Pharma and the mHealth Revolution -
engaging with mobile-enabled physicians and HCPs

It’s time to click on this.

The media’s dubbed them ‘a doctor in your pocket’ and ‘health care helpers’. Yet despite the explosion of mobile apps in other industries, pharma has generally been slow to exploit the possibilities they represent. What are the hurdles facing the industry and who are the leaders overcoming them? How can companies develop a mHealth approach that both addresses end-user needs and key messaging? What does pharma need to know about regulatory and legal hurdles?

Concisely written and expertly researched, this FirstWord Dossier report succinctly addresses the issues surrounding the emerging mHealth industry—and finds the answers.


Report Overview

Offering a compelling case for pharma to firmly establish its voice in mHealth, the report contains detailed insight into the opportunities app development represents. Encompassing the full range of questions demanded by the industry, the report includes expert insight from both those in pharma currently working ahead of the curve and mHealth developers themselves.

Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs has the answers.


Key Report Features

  • Convincing arguments for further involvement from pharma in developing mHealth apps for healthcare providers
  • Detailed insight into five major pharma mHealth projects
  • Methodologies for determining the platforms on which mHealth apps should be launched
  • Advice on how to maximise end-user needs to make mHealth products popular with health care professionals
  • Insight into navigating legal, regulatory and intellectual property issues
  • Solid predictions of future mHealth growth
  • Case study of how one major pharma company has evolved its mHealth strategy

Key Benefits

  • Discover how to develop an mHealth approach that aligns with company goals
  • Learn the key lessons of optimising apps and websites for healthcare providers
  • Learn how to navigate the main road bumps, including legal, regulatory and intellectual property issues
  • Gain insight into what the leaders in the field know and how they’re making mHealth apps work for them
  • Get access to detailed case studies from companies such as Eli Lilly, AstraZeneca, Johnson & Johnson, AliveCor and GSK

Key Questions Answered

  • When should a pharma company enter the mHealth market?
  • What approach should be taken in answering both company strategy and end-user needs?
  • What are the main hurdles facing the industry and how can they be overcome?
  • What realities do app designers for international markets face?
  • How can apps be developed for maximum usage across HCPs?
  • What are the guidelines for designing apps for tablet or smartphones?

Key Quotes

“The business case for pharma to engage in mHealth makes a lot of sense. But pharma has been quite slow to really embrace things in mobile health in a strategic or systematic way.” Dr. Patricia Mechael, executive director, mHealth Alliance

“There is substantial opportunity for pharmaceutical companies to be involved; it’s just that they have to walk that fine line between providing a service to the patient population and having what they’re doing viewed as just a kind of marketing.  As soon as it gets perceived as the latter, all the alarm bells will go off.” Dr. Satish Misra, managing editor, iMedicalApps


Order now for immediate online delivery -- Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs, a FirstWord Dossier ExpertViews report.

Need more information? Contact a consultant for an executive summary and sample pages from the report.


Publication date:
 February 2013
Product code:
 400200154
Format:
 PDF
Pages:
 83
Price:
$495 Single User License
?

Single user licenseAuthorizes use by the person placing the order only.


$2,475 Team License
?

Team licenseAuthorizes use by up to 10 employees of the Licensee who work within the same team or functional business unit.


$4,950 Global License
?

Global licenseAuthorizes use by any employee of the Licensee, including employees of the Licensee's affiliates.



Order Now

Who Should Read This Report?

  • Pharma medical affairs directors
  • Marketing executives
  • Compliance directors and legal teams
  • IT managers
  • PR firms with interests in the pharmaceutical industry
  • Digital marketing agencies
  • App and web designers

Expert Views

  • Dr. Dave Albert, Co-founder and Chief Medical Officer, AliveCor
  • Orion Armon, Partner, Cooley LLP
  • Kenneth Bennett, Senior Director, IS Business Partner, Sanofi US division
  • Lena Feygin, Managing Director, WeMultiply
  • Shwen Gwee, Vice President, Digital Health, Edelman
  • Peter Justason, Director, eMarketing, Purdue Pharma
  • Duncan Learmouth, Senior Vice President, Developing Countries & Market Access, GlaxoSmithKline
  • Jonathan Martin, Director of Education and Awareness Programs, National Marfan Foundation
  • Dr. Patricia Mechael, Executive Director, mHealth Alliance
  • Brian Meltzer, Executive Director, R&D Innovation, Purdue Pharma
  • Dr. Satish Misra, Managing Editor, iMedicalApps and member, Steering Committee, Johns Hopkins Global mHealth Initiative
  • Scott Morrison, Vice President, Information Systems, Boehringer Ingelheim
  • Judy Wade, ex-CEO, AliveCor

Table of Contents

  • Executive summary
  • Introduction
  • Possibilities
    > On the go
    > Device ownership
    > Medical practice has changed
    > Using mHealth devices
    > Topic diversity
    > Global diversity
  • Realities
    > The pioneers
    > Rules of engagement
    > Phone or web?
  • Pharma’s role in mHealth - Five detailed examples
    > Eli Lilly: Glucagon mobile app
    > AstraZeneca: EGFR mutation test
    > Johnson & Johnson: BlackBag
    > AliveCor: Heart monitor
    > GlaxoSmithKline: Mozambique vaccines programme
  • Case Study
    > Sanofi’s mHealth strategy
    > A variety of offerings
    > The bottom line
  • Uncertainties
    > Regulators weighing options
    > A Congressional approach
    > Intellectual property concerns
    > User hesitancy
  • What’s ahead?
    > Predicted growth
    > Emerging technology
    > Listening to the users
    > Assuring efficacy
    > The final requirement: Patience
  • Acknowledgements